From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates
Frontiers in Cellular and Infection Microbiology · 30.01.2026 · 15
DOI: 10.3389/fcimb.2025.1699057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 30.01.2026. Verfasst von Hai-Ting Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Indinavir, Antiviral Agents, Chlorhexidine, Zika Virus Infection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Zika virus (ZIKV) infection is associated with severe neurological complications, but no clinically approved antiviral therapies exist, leaving management reliant on symptomatic support. The essential NS2B/NS3 protease represents a promising drug target for ZIKV.
Methods
We performed structure-based virtual screening of 5,980 FDA-approved compounds from the ZINC database against the ZIKV NS2B/NS3 protease. Molecular docking identified 10 high-affinity candidates (LibDock score >150), which were subsequently evaluated for cytotoxicity and antiviral activity in Vero cells. The most promising compounds were further validated using immunofluorescence and Western blot assays. Their in vivo efficacy was assessed in a lethal AG6 mouse model.
Results
Chlorhexidine and indinavir exhibited potent anti-ZIKV activity in vitro, with EC50 values of 16.41 µM and 12.8 µM, respectively, and favorable selectivity indices (CC50: 57.56 µM and 38.96 µM). Both compounds demonstrated a dose-dependent inhibition of ZIKV replication (5–40 µM) at the protein level. In the AG6 mouse model, treatment with either compound (50 mg/kg/day) significantly prolonged survival (p<0.001), delayed disease-associated weight loss, and reduced viral loads in key tissues compared to untreated controls.
Discussion
Our integrated computational and experimental approach identifies chlorhexidine and indinavir as promising repurposed anti-ZIKV agents. While toxicity concerns require further investigation, these findings provide a validated foundation for the development of therapeutics against ZIKV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Pathogen Biology, Anhui Province Key Laboratory of Zoonoses, The Provincial Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei, Chin…
- Hunan Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology, Zhuzhou, China.
- Department of Disinfection and Vector Control, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.
Zitieren
APA
Zhang, H. T., Peng, Z. Y., Xiong, J. J., Luo, Y., Liu, J. H., Du, Y. N., Hou, Y. X., & Deng, S. Q. (2026). From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1699057
Vancouver
Zhang HT, Peng ZY, Xiong JJ, Luo Y, Liu JH, Du YN, et al. From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates. Frontiers in Cellular and Infection Microbiology. 2026;15. doi:10.3389/fcimb.2025.1699057
BibTeX
@article{Zhang2026,
author = {Zhang, Hai-Ting and Peng, Zhe-Yu and Xiong, Jun-Jun and Luo, Yang and Liu, Jia-Hua and Du, Yi-Nan and Hou, Yin-Xu and Deng, Sheng-Qun},
title = {From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {15},
doi = {10.3389/fcimb.2025.1699057}
}
EUVIMED